Proscia Enhances Preclinical R&D Platform: Streamlining Pathology Workflows for Faster Drug Safety Decisions

by Irina Bilous          Biopharma insight / News

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   1423    Comments
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email   |  

Proscia, a company specializing in digital and computational pathology solutions, recently announced updates to its preclinical research and development (R&D) offerings. These improvements target the company's flagship software platform, Concentriq® for Research, a tool many pharmaceutical companies use to manage pathology workflows and data. The expansion aims to streamline Good Laboratory Practice (GLP) and non-regulated drug safety studies, potentially influencing the industry.

Preclinical R&D is a crucial stage in drug development, determining if a drug is safe to proceed to human clinical trials. As life sciences organizations recognize the value of digital pathology in driving efficiency and quality gains in their routine operations, the demand for streamlined collaboration and improved reproducibility of results grows.

The enhancements to the Concentriq® for Research platform include new features and services, such as robust capabilities for GLP compliance, a new Studies module for more efficient toxicopathology workflows, and expanded Automated Quality Control (QC) for preclinical image data. These updates will enable organizations to conduct GLP and non-regulated studies on the same platform, manage study frameworks more effectively, collect pathologists' assessments, and evaluate results more efficiently.

The implementation of digital pathology solutions like Proscia's Concentriq® for Research reflects a broader trend in the pharmaceutical and biotechnology industries. As more organizations adopt artificial intelligence (AI) and data-driven approaches, the need for advanced tools to manage, analyze, and collaborate on pathology data becomes increasingly essential.

The use of such technologies can potentially reduce drug development timelines and costs, and accelerate the introduction of new therapies to the market. By focusing on preclinical R&D and enhancing the Concentriq® for Research platform, Proscia is contributing to the ongoing transformation of the drug development landscape.

Proscia's expanded Concentriq® for Research platform will be demonstrated at the Society of Toxicology 62nd Annual Meeting and ToxExpo, and during a live webinar on May 3, 2023, at 11 AM EDT. This opportunity allows industry professionals to explore the platform's updated features and assess how they may impact the future of preclinical R&D and drug safety studies.

Earlier this month, Proscia entered into a multi-year distribution agreement with Agilent Technologies Inc., a global leader in life sciences, diagnostics, and applied chemical markets. This collaboration aims to offer a comprehensive digital diagnostic pathology system by integrating Agilent's pathology staining solutions with Proscia's Concentriq Dx enterprise pathology platform.

 

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

Comments